As an integrative physician my office deals with patients with cancer quite a lot. We use many different tests to detect cancer
One of these tests is the Galleri early detection test. I have been using the test for some time But the results of a major study in England testing that hypothesis using the Galleri Multi-Cancer Early Detection (MCED) test just failed miserably.
In this study 142,000 healthy individuals age 50-77 conducted across the United Kingdom, patients underwent a Galleri blood test every year for 3 years. The intent was to detect early-stage (Stage I and II) cancer and provide earlier intervention before the cancers had spread.
The reality has proven quite different. The test failed to detect early cancer, falling short of a 20% reduction of Stage III and IV cancers, the study design’s statistical endpoint.
This is not surprising as a review of the Galleri DNA blood test’s sensitivity for detection in early-stage cancer has been known to be quite low, in the range of 15-20%. This has not prevented the company from selling the test to the public.
“This Study failed, end of story.”
This was evaluated and published in the Townsend Letter
Until tomorrow…